CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Chembio Diagnostics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Chembio Diagnostics Inc
555 Wireless Blvd
Phone: (631) 924-1135p:631 924-1135 HAUPPAUGE, NY  11788  United States Fax: (775) 884-9383f:775 884-9383
This company was Merged or Acquired on 4/27/2023.
This company ceased filing statements with the SEC on 5/9/2023.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Chembio Diagnostics, Inc. is a diagnostics company. The Company is focused on developing and commercializing point-of-care tests used to detect and diagnose infectious diseases, including sexually transmitted diseases, insect vectors and tropical diseases, coronavirus disease (COVID-19), and other viral and bacterial infections, enabling expedited treatment. The Company's DPP technology offers broad market applications beyond infectious disease. The DPP platform can detect and differentiate up to eight distinct test results from a single patient sample. Its DPP Micro Reader optical analyzers can report results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still on site. Its products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202212/31/2022YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
2835 In vitro and in vivo diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Katherine L.Davis 65 7/1/2020 5/10/2007
President, Chief Executive Officer, Director Richard L.Eberly 61 1/5/2022 3/16/2020
Chief Financial Officer Lawrence J.Steenvoorden 52 1/5/2022 1/5/2022
7 additional Officers and Directors records available in full report.

Business Names
Business Name
CEMI
Chembio Diagnostic Systems Inc.
Chembio Diagnostic Systems, Inc.
8 additional Business Names available in full report.

General Information
Number of Employees: 188 (As of 12/31/2022)
Outstanding Shares: 36,725,858 (As of 3/24/2023)
Shareholders: 114
Stock Exchange: NASD
Federal Tax Id: 880425691
Fax Number: (775) 884-9383


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, April 16, 2024